...
首页> 外文期刊>Cell metabolism >Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells
【24h】

Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells

机译:联合抑制甲醛,Smad和Trithorax途径的协同促进成人人β细胞中的鲁棒复制

获取原文
获取原文并翻译 | 示例
           

摘要

Small-molecule inhibitors of dual-specificity tyrosine-regulated kinase 1A (DYRK1A) induce human beta cells to proliferate, generating a labeling index of 1.5%-3%. Here, we demonstrate that combined pharmacologic inhibition of DYRK1A and transforming growth factor beta superfamily (TGF beta SF)/SMAD signaling generates remarkable further synergistic increases in human beta cell proliferation (average labeling index, 5%-8%, and as high as 15%-18%), and increases in both mouse and human beta cell numbers. This synergy reflects activation of cyclins and cdks by DYRK1A inhibition, accompanied by simultaneous reductions in key cell-cycle inhibitors (CDKN1C and CDKN1A). The latter results from interference with the basal Trithorax-and SMAD-mediated transactivation of CDKN1C and CDKN1A. Notably, combined DYRK1A and TGF beta inhibition allows preservation of beta cell differentiated function. These beneficial effects extend from normal human beta cells and stem cell-derived human beta cells to those from people with type 2 diabetes, and occur both in vitro and in vivo.
机译:双特异性酪氨酸调节激酶​​1a(Dyrk1a)的小分子抑制剂诱导人β细胞增殖,产生1.5%-3%的标记指数。在这里,我们证明了Dyrk1a和转化生长因子β超家族(TGFβSF)/ smad信号传导的组合药理学抑制产生了显着的进一步协同增加(平均标记指数,5%-8%,高达15 %-18%),并增加鼠标和人β细胞数。该协同作用反映了Dyrk1a抑制的Cyclins和Cdks的激活,伴随着关键细胞周期抑制剂(CDKN1C和CDKN1A)的同时降低。后一种结果由干扰对CDKN1C和CDKN1A的基底晶体和Smad介导的转移产生。值得注意的是,组合的DyRK1A和TGFβ抑制允许保存β细胞分化功能。这些有益的效果从正常人β细胞和干细胞衍生的人β细胞延伸到来自2型糖尿病患者的人的人β细胞,并且在体外和体内发生。

著录项

  • 来源
    《Cell metabolism》 |2019年第3期|共15页
  • 作者单位

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Columbia Univ Naomi Berrie Diabet Ctr New York NY 10032 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Semma Therapeut Cambridge MA 02142 USA;

    Semma Therapeut Cambridge MA 02142 USA;

    Semma Therapeut Cambridge MA 02142 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Columbia Univ Naomi Berrie Diabet Ctr New York NY 10032 USA;

    Icahn Sch Med Mt Sinai Icahn Inst Genom &

    Multiscale Biol Dept Genet &

    Genom Sci New York NY;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

    Icahn Sch Med Mt Sinai Diabet Obes &

    Metab Inst New York NY 10029 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内分泌腺疾病及代谢病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号